You are here:Home-Research Areas-Cardiovascular Disease-Atherosclerosis

Request The Product List ofAtherosclerosis Atherosclerosis

Cat. No. Product Name CAS No. Information
PC-45118

Terutroban

165538-40-9

Terutroban (S-18886) is a potent, selective antagonist of the thromboxane receptor (Prostanoid TP receptor) that blocks thromboxane induced platelet aggregation and vasoconstriction;

Atherosclerosis

Phase 3 Clinical

PC-43317

MK-0354

851776-28-8 MK-0354 is a potent, selective niacin receptor GPR109A partial agonist with EC50 of 1.65 and 1.08 uM for hGPR109A and mGPR109A in the whole cell cAMP assays; shows no interaction with any other target in a panel of over 120 other proteins; MK-0354 is a competitive inhibitor of 3H-nicotinic acid binding to hGPR109a with Ki of 505 nM, fully inhibits isoproterenol stimulated lipolysis in human adipocytes with IC50 of 3.1 uM, also is a competitive antagonist of nicotinic acid-induced MAPK signaling in cells overexpressing either mGPR109a or hGPR109a; possesses plasma FFA lowering effects in mice comparable to those of nicotinic acid, does not induce vasodilation.

Atherosclerosis

Phase 2 Discontinued

PC-42893

Anacetrapib

875446-37-0 Anacetrapib (MK 0859) is a potent, orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50 of 7.9 nM and 11.8 nM for rhCETP and C13S CETP mutant, respectively; inhibits CETP-mediated cholesterol exchange, resulting in elevated HDL-cholesterol levels and reductions in LDL-cholesterol levels, demonstrates potential to treat elevated cholesterol levels in an effort prevent cardiovascular disease.

Atherosclerosis

Phase 3 Clinical

PC-42892

Torcetrapib

262352-17-0 Torcetrapib (CP-529414) is a potent cholesteryl ester transfer protein (CETP) inhibitor with IC50 of 37 nM; shows the potential to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.

Atherosclerosis

Phase 2 Discontinued

PC-63003

SB-435495

304694-39-1 SB-435495 is a potent, orally active inhibitor of Lp-PLA2 with IC50 of 0.06 nM; inhibits the enzyme in whole human plasma with IC50 of 3 nM; shows little interaction with other CYP450 enzymes (CYP450 IC50: 1A2>100 mM, 2C9>100 uM, 2C19>40 uM, 2D6=37 uM); effectively suppresses BRB breakdown in streptozotocin-diabetic Brown Norway rats,.

Atherosclerosis

Phase 2 Discontinued

PC-62954

K-604

217094-32-1 K-604 is a potent, selective and competitive ACAT-1 inhibitor with IC50 of 0.45 uM for human ACAT-1, displays 229-fold selectivity over ACAT-2; inhibits cholesterol esterification in human monocyte-derived macrophages with IC50 of 60 nM, enhances cholesterol efflux from THP-1 macrophages to HDL3 or apolipoprotein A-I; suppresses the development of atherosclerosis in an animal model without affecting plasma cholesterol levels.

Atherosclerosis

Phase 2 Clinical

PC-62403

CI-976

114289-47-3 CI-976 (PD 128042) is a potent, selective, orally bioavailable inhibitor of ACAT-1 (Acetyl-CoA acetyltransferase 1) with IC50 of 73 nM; decreases plasma total cholesterol, very low density lipoprotein (VLDL) cholesterol, LDL cholesterol, apolipoprotein B, liver cholesteryl esters, and VLDL and LDL cholesteryl ester content in rabbits.

Atherosclerosis

Discontinued

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com